CRE_Bispecific_Antibody_CRS_and_ICANS_Neurotoxicity_Guidance_Feb2024 51899285fnl_Immunotoxic Potential of PharmaceuticalsWe are considering Bispecific T cell engagers (BiTEs) [1] as an alternative to a CAR T driven cytokine release as an immunotherapy focused DDT. BiTEs are monoclonal antibodies engineered to have one arm that recognizes a…
